Clinical Benefits of a Randomized Allergy App Intervention in Grass Pollen Sufferers: A Controlled Trial
Allergy · 2025
DOI: 10.1111/all.16558 ↗At a glance
Randomisierte kontrollierte Studie in Allergy, 2025. Written by Caroline Holzmann and 13 co-authors. Institution: Institute of Environmental Medicine and Integrative Health, Faculty of Medicine, University Hospital Augsburg, Augsburg, Germany. Major MEDLINE topics: Rhinitis, Allergic, Seasonal, Pollen, Mobile Applications, Poaceae. Cited 8 times so far (Crossref); 33 references. The full text is freely available (open access, CC BY 4.0). Funded by: Bayerisches Landesamt für Gesunheit und Lebensmittelsicherheit (LGL), German Ministry of Research and Education (BMBF).
Abstract (original language)
Background
Symptom monitoring can improve adherence to daily medication. However, controlled clinical trials on multi‐modular allergy apps and their various functions have been difficult to implement. The objective of this study was to assess the clinical benefit of an allergy app with varying numbers of functions in reducing symptoms and improving quality of (QoL) life in grass pollen allergic individuals. The secondary objective was to develop a symptom forecast based on patient‐derived and environmental data.
Methods
We performed a stratified, controlled intervention study (May–August 2023) with grass pollen allergic participants ( N = 167) in Augsburg, Germany. Participants were divided into three groups, each receiving the same allergy app, but with increasing numbers of functions. Primary endpoint: rhinitis‐related QoL; Secondary endpoints: symptom scores, relevant behavior, self‐reported usefulness of the app, symptom forecast.
Results
Rhinitis‐related QoL was increased after the intervention, with no statistical inter‐group differences. However, participants with access to the full app version, including a pollen forecast, took more medication and reported lower symptoms and social activity impairment than participants with access to a reduced‐function app. Using an XGBoost multiclass classification model, we achieved promising results for predicting nasal (accuracy: 0.79; F1‐score: 0.78) and ocular (accuracy: 0.82; F1‐score: 0.76) symptom levels and derived feature importance using SHAP as a guidance for future approaches.
Conclusion
Our allergy app with its high‐performance pollen forecast, symptom diary, and general allergy‐related information provides a clinical benefit for allergy sufferers. Reliable symptom forecasts may be created given high‐quality and high‐resolution data.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Institute of Environmental Medicine and Integrative Health, Faculty of Medicine, University Hospital Augsburg, Augsburg, Germany.
- Institute of Environmental Medicine, Helmholtz Munich-German Research Center for Environmental Health, Augsburg, Germany.
- Outpatient Clinic for Environmental Medicine, University Hospital Augsburg, Augsburg, Germany.
- Institute for Digital Medicine, University Hospital Augsburg, Augsburg, Germany.
- Department of Technology, Management, and Economics, Technical University of Denmark, Copenhagen, Denmark.
- Next Generation Technology, Region Zealand, Denmark.
ORCID profiles: Gertrud Hammel, Athanasios Damialis
Funding
- Bayerisches Landesamt für Gesunheit und Lebensmittelsicherheit (LGL)
- German Ministry of Research and Education (BMBF)
Cite
APA
Holzmann, C., Karg, J., Reiger, M., Kharbal, R., Romano, P., Scheiwein, S., Khalfi, C., Muzalyova, A., Brunner, J. O., Hammel, G., Damialis, A., Traidl-Hoffmann, C., Plaza, M. P., & Gilles, S. (2025). Clinical Benefits of a Randomized Allergy App Intervention in Grass Pollen Sufferers: A Controlled Trial. Allergy. https://doi.org/10.1111/all.16558
Vancouver
Holzmann C, Karg J, Reiger M, Kharbal R, Romano P, Scheiwein S, et al. Clinical Benefits of a Randomized Allergy App Intervention in Grass Pollen Sufferers: A Controlled Trial. Allergy. 2025. doi:10.1111/all.16558
BibTeX
@article{Holzmann2025,
author = {Holzmann, Caroline and Karg, Johannes and Reiger, Matthias and Kharbal, Rajiv and Romano, Paola and Scheiwein, Sabrina and Khalfi, Claudia and Muzalyova, Anna and Brunner, Jens O and Hammel, Gertrud and Damialis, Athanasios and Traidl-Hoffmann, Claudia and Plaza, María P and Gilles, Stefanie},
title = {Clinical Benefits of a Randomized Allergy App Intervention in Grass Pollen Sufferers: A Controlled Trial},
journal = {Allergy},
year = {2025},
doi = {10.1111/all.16558}
}
EUVIMED